Genitourinary Cancers | Specialty

Dr. Robert Motzer Reviews the Phase III COMPARZ Study

March 5th 2013

Robert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the COMPARZ trial that compared pazopanib to sunitinib as a first-line therapy for patients with metastatic renal cell carcinoma.

Dr. Gomella on the Value of a Multidisciplinary Cancer Center

February 27th 2013

Leonard G. Gomella, MD, discusses the benefits of the multidisciplinary center at Jefferson Kimmel Cancer Center.

Dr. Kamat on a Molecular Definition of BCG Failure

February 26th 2013

Ashish M. Kamat, MD, from MD Anderson Cancer Center, discusses enhancing clinical trial recruitment through a novel definition of BCG therapy failure in patients with nonmuscle invasive bladder cancer.

Targeted Therapies, Multidrug Regimens, and Standardized Drug Development Efforts Needed in Nonmuscle-Invasive Bladder Cancer

February 26th 2013

Collaborative and standardized efforts to develop and evaluate novel drugs are necessary to ultimately provide effective long-term treatment for nonmuscle-invasive bladder cancer.

Partial Nephrectomy Remains Underutilized, Despite AUA Endorsement

February 26th 2013

Although the 2009 AUA guidelines cite "compelling data" for consideration of nephron-sparing surgery in all patients, partial nephrectomy remains underutilized for small renal masses.

Dr. Deepak Kapoor on Integrated Urology Practices

February 21st 2013

Deepak A. Kapoor, MD, president of the Large Urology Group Practice Association, discusses the greater exposure to high-quality healthcare that is provided by the integration of ancillary services into community urology practices.

Dr. Galsky on a Post-Treatment Nomogram in Urothelial Cancer

February 20th 2013

Matthew D. Galsky, MD, from the Mount Sinai Medical Center Tisch Cancer Institute, discusses the development of a post-treatment prognostic model for patients with metastatic urothelial cancer.

Dr. Weiss on PPAR-Alpha as a Target in Kidney Cancer

February 19th 2013

Robert H. Weiss, MD, from the UC Davis Comprehensive Cancer Center, discusses peroxisome PPAR-alpha as a possible new treatment target for patients with renal cell carcinoma.

Dr. Huang Compares Surveillance and Treatment in Kidney Cancer

February 18th 2013

William C. Huang, MD, from the New York University Langone Medical Center, discusses findings from a SEER database analysis that compared surveillance to surgical resection in elderly patients with small renal masses.

PFS Not Significantly Better With First-Line Axitinib Versus Sorafenib in mRCC

February 16th 2013

Axitinib did not demonstrate superiority over sorafenib as first-line therapy for patients with metastatic renal cell carcinoma, on the endpoint of progression-free survival.

Tandems of Targeted Therapy No Better Than Bevacizumab Alone in Advanced Renal Cell Carcinoma

February 16th 2013

Combination targeted therapy did not significantly extend progression-free survival compared with single-agent bevacizumab in patients with advanced renal cell carcinoma.

Dr. Motzer Analyzes Overall Survival in the TIVO-1 Study

February 15th 2013

Robert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the overall survival results from the phase III TIVO-1 study that compared tivozanib to sorafenib in patients with renal cell carcinoma.

Dr. Deepak Kapoor on the Utilization of Prostate Biopsies

February 14th 2013

Deepak A. Kapoor, MD, president of the Large Urology Group Practice Association, discusses the implications of a large study looking at the detection of prostate cancer using prostate biopsies.

A United Front: Chesapeake Urology Associates Puts Its Singular Spin on Integrative Care

January 17th 2013

When the founding partners of Chesapeake Urology Associates (CUA) in Maryland decided to merge their practices, Sanford J. Siegel, MD, CUA's president and CEO, drew inspiration from another consolidation process.

Multidisciplinary Prostate Cancer Care at Duke Cancer Institute: An Interview With Judd W. Moul, MD

January 16th 2013

Judd W. Moul, MD, from the Duke Cancer Institute, comments on practice trends in urologic cancer care and the advantages and disadvantages of his institution's multidisciplinary prostate cancer clinic.

Dr. Sridhar on Nab-Paclitaxel in Urothelial Cancer

January 10th 2013

Srikala Sridhar, MD, MSc, from the University of Toronto, Canada, discusses the results of a single arm phase II trial examining nab-paclitaxel as a secondary treatment for urothelial cancer.

Nab-Paclitaxel Continues to Be Explored in Advanced Urothelial Cancer

January 3rd 2013

Nab-paclitaxel might offer some hope for patients with advanced urothelial cancer, an area that has lagged behind the rapid growth in available therapies for other genitourinary cancers.

The Challenges That Lie Ahead

December 13th 2012

As many of us are keenly aware, the coming 12 months present some very challenging times in the medical community.

The USPSTF Prostate Cancer Screening Recommendations: Urologists Discuss Its Message and Impact on Their Practices

December 12th 2012

A panel of experts provides their thoughts on the USPSTF PSA screening recommendations, and how this widely publicized health message has impacted their urology practices.

Dr. Shore on Current Clinical Trial Challenges in CRPC

December 12th 2012